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A molecular variant of the angiotensinogen gene encoding methionine in-
stead of threonine at position 174 (T174M) has been associated with essen-
tial hypertension (HTN) in case-control studies. We examined the relations of
the T174M allele with HTN in 1401 subjects (707 men, 694 women) from the
Framingham Offspring Study (mean age 50.5, range 25-78 years). Pooled-
and sex-specific simple association analyses revealed no relation between
hypertension status and presence or absence of T174M. Conditional logistic
regression was used to analyze the relations of T174M to HTN in 143 sib-
ships in which at least 1 sibling had HTN. After adjusting for sex and age,
presence of T174M was associated with a nonsignificant increase in proba-
bility of HTN (OR 1.89, 95% CI 0.83-4.29, P = 0.13). Analysis of 25 affected
sibling-pairs with severe HTN suggested an excess sharing of the T174M
allele (p = 0.056).
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gaps. The two populations had similar systolic and diastolic blood pressures,
serum lipid levels and smoking history. Logistic regression analysis including
age in the model indicated that only female gender, beta (an index of arte-
rial stiffness) and the presence of plaque were independently related to the
presence of auscultatory gaps. This study provides the first evidence that
auscultatory gaps are related to the presence of carotid atherosclerosis and
to increased arterial stiffness in hypertensive patients, independently of age.
Although these observations need to be confirmed by prospective studies
they suggest a prognostic relevance of the auscultatory gaps.
ABSTRACTS
SBPDBP HR PV
6 r-------::::----,
24A
Pre-Donation Post-Donation Change Significance
HRI/min) 68.5 ± 1.5 69.8 ± 1.5 1.4 ± 0.6 p < 0.02
SBP(mmHg) 143.1 ± 2.5 1458 ± 3.1 2.9 ± 2.3 n.s
DBP(mmHg) 732 ± 2.0 75.7 ± 1.7 1.9 ± 1.5 n.s.
PVIJ.!LI 1151 ± 64 954 ± 39 -197 ± 53 p < 0.0001
There were no significant changes in either SBP or DBR The HR increased
significantly, but by only 2.0% (p < 0.02). The PV decreased by 17.1 % (p <
0.0001), which is 8.6 times greater than the percent change in heart rate (p
< 0.01). The PV decrease correlated with the blood loss per kg (r = 0.46, p
< 0.01). We conclude that a significant change in PV occurs with relatively
minor blood loss. Pulse volume analysis may therefore provide an early indi-
cation of hypovolemia due to acute blood loss.
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Borderline Isolated Systolic Hypertension and
Subsequent Risk of Cardiovascular Disease
Christopher J. O'Donnell, Paul M. Ridker, Klaus Berger, Frances LaMotte, Robert
J. Glynn, JoAnn E. Manson, Charles H. Hennekens. Division of Preventive Medicine,
Brigham and Women's Hospital, Boston, MA
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Mean 195% CII* P < 0.05. ** P< 0.01, STD = ST Segment Depression
ISCHEMIC HEART DISEASE - CHRONIC/SILENT ISCHEMIA
AA = normal. Aa ~ presence of 1T174M allele, aa = presence of 2T174M alleles. Severe
HTN = systolic BP ~ 160 mmHg or diastolic BP ~ 100 mmHg or use of ~2 anti-HTN
medications. Mild HTN ~ systolic BP ~ 140 mmHg or diastolic BP ~ 90 mmHg or use of
a single anti-HTN medication.
Ranolazine Dose Group minus Placebo Group Responses
267 mg tid 400 mg bid 400 mg tid
231 S,38)** 19( 4, 34)* 19 ( 4, 341*
1212,23) 10(-06,20) 10{-01,201
25111,39)** 17( 3. 31)* 22( 8, 361**
1.1% -0.3% 1.9%
A Multicenter Controlled Trial of a Novel
Metabolic Active Compound (Ranolazine) in
Chronic Stable Angina Patients
Conclusions: In this large noninstitutionalized sample, we did not find an
association between the T174M allele and HTN. In a subset of 25 sibships
with severe HTN, however, genetic linkage between the angiotensinogen
locus and severe HTN was suggested.
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Ranolazine significantly increased times to onset of both angina and ST
segment depression at all doses tested. All exercise parameters were sig-
nificantly (P :5 0.01) improved with ranolazine at peak plasma levels com-
pared with placebo as ranolazine plasma levels ranged from 1,350 to 2,130
William B. Smith, Steven Chrysant, William 1. Garland, Thomas S. Parker, Howard
1. Walpole, Ahmad Mokatrin 1, Daniel Gennevois 1, Carl J. Pepine, Syntex
Ranolazine Study Group. University ofFlorida, Gainesville, FL
Ranolazine is a new antianginal agent believed to reduce oxygen demand
through its metabolic action without effects on blood pressure, heart rate
or cardiac function. It was evaluated in a randomized, double-blind, placebo-
controlled, crossover trial with an extended-period Latin square design (5
one week periods). During a placebo phase, 312 patients with chronic stable
angina (:::3 months) receiving multiple antianginals were withdrawn from::: 1
antianginal drugs. After their exercise time had shortened by :::1.0 mins they
were randomized to receive either ranolazine 267 mg tid, 400 mg bid, 400 mg
tid or placebo during each study period. After 1 week of treatment exercise
tolerance (Bruce protocol) and plasma ranolazine levels were measured at
peak (1 hr after dosing) and at trough (8 [tid] or 12 [bid] hr after dosing).
Results at Peak Ranolazine Blood Level
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Auscultatory Gaps and Target Organ Damage in
Hypertensive Patients
M. Chiara Cavallini, Mary J. Roman, Seymour G. Blank, Riccardo Pini, Thomas
G. Pickering, Richard B. Devereux. The New York Hospital-Cornell University Medical
Center, New York, NY
Guidelines are unclear about treatment of borderline isolated systolic hyper-
tension, defined as both systolic BP 140-159 mmHg and diastolic BP < 90
mmHg. We investigated the association between borderline isolated sys-
tolic hypertension and subsequent risk of myocardial infarction (MI), stroke,
cardiovascular death, and the combined endpoint of important cardiovas-
cular events (nonfatal MI, nonfatal stroke or cardiovascular death) among
22,071 men age 40-84 years followed prospectively for an average of 10.7
years in the Physician's Health Study. Baseline BP and cardiovascular risk fac-
tors were available from completed questionnaires on 16,678 men among
whom 960 subsequently had an incident important cardiovascular event. In
proportional hazards models adjusting for other cardiovascular risk factors,
the relative risks were calculated for those with borderline isolated systolic
hypertension relative to those with both systolic BP < 140 mmHg and dias-
tolic BP < 90 mmHg. These relative risks were 1.05 (95% confidence interval
CI 0.80 to 1.36) for MI, 1.68 (95% CI 1.24 to 2.26) for stroke, 1.61 (95% CI
1.19 to 2.18) for cardiovascular death, and 1.32 (95% CI 1.11 to 1.58) for the
combined endpoint of important cardiovascular events. These associations
were not altered by an analysis excluding participants who reported baseline
treatment for hypertension.
Conclusion: Borderline isolated systolic hypertension is associated with a
significantly increased risk of subsequent important cardiovascular events.
Auscultatory gaps are a common finding in clinical practice but their clinical
and prognostic importance has never been assessed. To examine the rela-
tion of auscultatory gaps to left ventricular and arterial structure and function,
wideband external pulse recordings during cuff deflation to detect ausculta-
tory gaps and ultrasonographic examination of left ventricle and extracranial
carotid artery were performed in 168 unmedicated, asymptomatic hyperten-
sive subjects. Vascular stiffness was also evaluated by simultaneous carotid
pressure waveforms obtained by applanation tonometry of the contralateral
carotid artery. Auscultatory gaps were present in 21 % of the population and
were associated with older age (64 ± 11 vs 55 ± 13 years, p < 0.0005). fe-
male gender (66 vs 44%, p < 0.05) and increased arterial stiffness (beta = 8.5
± 4.6 vs 5.8 ± 3.2, P < 0.005). Differences in arterial stiffness persisted after
controlling for the confounding effects of age and gender. The prevalence of
atherosclerotic plaques was more than two-fold increased among subjects
with gaps (50 vs 22%, p < 0.005). No significant differences were found in
left ventricular structure and function between the subjects with and without
